Literature DB >> 29962381

Clinical and Economic Analysis of Lipid Goal Attainments in Chinese Patients with Acute Coronary Syndrome Who Received Post-Percutaneous Coronary Intervention.

Yun Wang1, Bryan Ping Yen Yan2, Brian Tomlinson3, Michael Bruce Nichol4, Vivian Wing Yan Lee1.   

Abstract

AIM: The recommended low-density lipoprotein cholesterol (LDL-C) levels of the guideline may be appropriate for Caucasian patients but not for other ethnic groups.
METHODS: A cohort study was conducted in Hong Kong, and acute coronary syndrome (ACS) patients who received percutaneous coronary intervention (PCI) between 2005 and 2015 were enrolled. The primary outcomes of interest were the total cost of care and cardiovascular-related cost during one-year follow-up. The cost difference by lipid goal attainments was analyzed by Poisson regression with multivariate treatment effects. The clinical outcomes achieved by lipid goal attainments in terms of major adverse cardiovascular events were analyzed by multivariate Cox regression.
RESULTS: Among the 4638 patients, 79.50%, 48.64%, and 36.14% attained the LDL-C goals of <2.6, <2.0, and <1.8 mmol/L for one year, respectively. Only about 16% patients achieved the ≥50% reduction from baseline. None of these lipid goals was associated with a significant reduction in the total cost of care. We only identified the clinical benefits associated with the lipid goal of <2.6 mmol/L. Other more stringent lipid goals seemed to bring a significant economic burden on cardiovascular-related cost, but their clinical benefits were uncertain.
CONCLUSIONS: Lowering LDL-C to achieve the guideline-recommended target levels for post-PCI ACS patients may lead to fewer cardiovascular events, but it may not necessarily lead to economic benefits within one year of follow-up.

Entities:  

Keywords:  Cardiovascular events; Chinese; Cost analysis; Cost of care; LDL-C

Mesh:

Substances:

Year:  2018        PMID: 29962381      PMCID: PMC6249357          DOI: 10.5551/jat.44818

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.928


  43 in total

1.  The California Cardiac Surgery and Intervention Project: evolution of a public reporting program.

Authors:  Joseph S Carey; Beate Danielsen; Forrest L Junod; Stephen J Rossiter; Bruce E Stabile
Journal:  Am Surg       Date:  2006-10       Impact factor: 0.688

2.  2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Monica M Colvin; Mark H Drazner; Gerasimos Filippatos; Gregg C Fonarow; Michael M Givertz; Steven M Hollenberg; JoAnn Lindenfeld; Frederick A Masoudi; Patrick E McBride; Pamela N Peterson; Lynne Warner Stevenson; Cheryl Westlake
Journal:  Circulation       Date:  2016-05-20       Impact factor: 29.690

3.  Association Between Achieved Low-Density Lipoprotein Levels and Major Adverse Cardiac Events in Patients With Stable Ischemic Heart Disease Taking Statin Treatment.

Authors:  Morton Leibowitz; Tomas Karpati; Chandra J Cohen-Stavi; Becca S Feldman; Moshe Hoshen; Haim Bitterman; Samy Suissa; Ran D Balicer
Journal:  JAMA Intern Med       Date:  2016-08-01       Impact factor: 21.873

4.  Real-world study of low-density lipoprotein cholesterol levels and cardiovascular outcomes in Chinese: A retrospective cohort study in post-percutaneous coronary intervention acute coronary syndrome patients.

Authors:  Yun Wang; Bryan P Yan; Michael B Nichol; Brian Tomlinson; Vivian W Y Lee
Journal:  Int J Cardiol       Date:  2017-12-15       Impact factor: 4.164

5.  Differential prognostic impacts of diabetes over time course after acute myocardial infarction.

Authors:  Hack-Lyoung Kim; Si-Hyuck Kang; Chang-Hwan Yoon; Young-Seok Cho; Tae-Jin Youn; Goo-Yeong Cho; In-Ho Chae; Hyo-Soo Kim; Shung-Chull Chae; Myeong-Chan Cho; Young-Jo Kim; Ju Han Kim; Youngkeun Ahn; Myung Ho Jeong; Dong-Ju Choi
Journal:  J Korean Med Sci       Date:  2013-11-26       Impact factor: 2.153

6.  The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals.

Authors:  T A Pearson; I Laurora; H Chu; S Kafonek
Journal:  Arch Intern Med       Date:  2000-02-28

7.  Noncardiac surgery for patients with coronary artery stents: timing is everything.

Authors:  Jeffrey J Rade; Charles W Hogue
Journal:  Anesthesiology       Date:  2008-10       Impact factor: 7.892

8.  Early readmissions after percutaneous coronary intervention in a rural tertiary care center (from the Guthrie Health Off-label Stent [GHOST] Registry).

Authors:  Kishore J Harjai; Maninder Singh; Judy Boura
Journal:  Am J Cardiol       Date:  2012-05-11       Impact factor: 2.778

Review 9.  Racial Differences in the Cholesterol-Lowering Effect of Statin.

Authors:  Ryo Naito; Katsumi Miyauchi; Hiroyuki Daida
Journal:  J Atheroscler Thromb       Date:  2016-10-12       Impact factor: 4.928

10.  Statin Responses in Chinese Patients.

Authors:  Brian Tomlinson; Paul Chan; Zhong-Min Liu
Journal:  J Atheroscler Thromb       Date:  2017-07-21       Impact factor: 4.928

View more
  2 in total

1.  Serum Calprotectin Levels and Outcome Following Percutaneous Coronary Intervention in Patients with Diabetes and Acute Coronary Syndrome.

Authors:  Chengji Wang; Yu Kong; Yuanyuan Ding; Jingzhi Sun; Tao Chen
Journal:  Med Sci Monit       Date:  2019-12-13

2.  Prognostic value of serum calprotectin level in elderly diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: A Cohort study.

Authors:  Wutang Zhang; Yongmei Kong; Lizhi Wang; Lizhong Song; Lijuan Tan; Xiaobo Xue
Journal:  Medicine (Baltimore)       Date:  2020-08-14       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.